Cellestia Biotech: A novel method from Basel to fight cancer
Michael Bauer, CEO of Cellestia Biotech (Img: Cellestia Biotech AG)
Some varieties of cancer don’t have a specific therapy available to date. Cellestia Biotech AG is aiming to change this for the worldwide over 250’000 patients who are annually diagnosed with so-called “NOTCH dependent” cancers. “NOTCH” is a cell-to-cell communication or signaling pathway, which plays a central role in cell differentiation, growth and stem cell maintenance. If it is inappropriatelyinaptly activated by mutations, the signaling pathway becomes a major driver for NOTCH-dependent cancers. Cellestia is currently developing CB-103, a novel, first-in-class, oral pan-NOTCH inhibitor with a unique mode of action for treatment.
Office in Basel, research labs in Lausanne
The company has a principal office at the Technologiepark Basel and is conducting research at the Ecole Polytechnique Fédérale de Lausanne (EPFL) laboratories. “Cellestia was founded in 2014 as a spin-off from EPFL by Prof. Freddy Radtke and Dr. Rajwinder Lehal”, explains Michael Bauer, CEO of Cellestia Biotech AG. “In 2015, a team of senior pharma executives - including myself - joined the company as investors and co-founders.” That was when the company opened its head office in Basel.
Dr. Rajwinder Lehal
(Img: Cellestia Biotech AG)
“Basel provides us excellent networking opportunities and offers great infrastructure, it’s also a top location for fundraising and has access to a highly professional talent pool”, lists Bauer as the reasons for moving to the city at the Rhine river. “And not to forget is the vicinity to big pharma such as Roche and Novartis”, he adds. But the search for an ideal location was difficult. “Rentals in Basel are priced high, and ideal offices are scarce”, says Bauer.
Phase I for lead candidate CB-103
In the end, they found their ideal location in the Technologiepark Basel. “It’s great for a start-up like us: You get a plug-and-play set-up, a dynamic environment and first-class infrastructure at an affordable price.” Michael Bauer calls it “an ideal biotope” where they even knew some of their neighbors from earlier projects.
(Img: Technologiepark Basel AG)
“We can only recommend the Technologiepark Basel for innovative life sciences start-ups”, he sums up.
And indeed, setting up at the Technologiepark Basel seems to work for Cellestia: The company has reached clinical development stage and treated their first cancer patients in December 2017 in the ongoing Phase l-lla first-in-man clinical trial with CB-103. Michael Bauer hopes to conclude Phase I by mid-2019, starting with Phase II shortly after.
“It’s still far away, but we hope that by 2022, Cellestia Biotech AG will reach approval for our first product.”